Differential Reconstitution of T Cell Subsets Following Immunodepleting Treatment With Alemtuzumab (Anti-Cd52 Monoclonal Antibody) in Patients With Relapsing-Remitting Multiple Sclerosis
Journal of Immunology- United States
doi 10.4049/jimmunol.1301926
Full Text
Abstract
Available in
Date
November 6, 2013
Authors
Publisher
The American Association of Immunologists